Antibodies for allergy and complement disease

LongBio Pharma is a biotechnology company that specializes in the development of innovative drugs targeting allergy and complement diseases. The company has established a robust pipeline of products, including the InCibitor™ platform, which focuses on complement inhibition. This platform has led to the development of LP-005, a bi-functional complement inhibitor that is set to enter Phase II/III clinical studies in 2024. LongBio's research extends beyond allergy treatments, exploring applications in hematology, nephrology, neurology, ophthalmology, oncology, and gene therapy, with a commitment to addressing unmet clinical needs and enhancing patient care.

In addition to its complement inhibition efforts, LongBio Pharma is also advancing LP-003, an anti-IgE antibody aimed at treating IgE-mediated allergic diseases. This product is grounded in a deep understanding of the immunological mechanisms involved in allergic conditions, particularly asthma. The company is leveraging its expertise to develop therapies that not only target specific pathways but also offer improved pharmacokinetic and pharmacodynamic properties, thereby enhancing the efficacy and safety of its treatments. LongBio Pharma's focus on innovative solutions positions it as a competitive player in the biopharmaceutical landscape, dedicated to delivering high-quality and affordable biomedicines to patients globally.

China

Longbio Pharma is founded in 2018, and located in Zhangjiang Hi-tech Park, Shanghai. There are 40+ scientists, 10+years experiences in protein drug development (antibodies and fusion proteins) .The co-founder team successfully developed two drugs for marketing (accumulated global sales USD 30 Billion). Longbio Pharma is focusing on R&D the innovative drugs of autoimmune and rare diseases (allergy and complement).

Longbio Pharma

Company Details